BioWorld - Wednesday, February 4, 2026

BioWorld Science

Nov. 7, 2005

View Archived Issues

Millennium updates pipeline progress

Read More

Locteron begins phase I study for chronic hepatitis C

Read More

Satraplatin begins phase II study in metastatic breast cancer

Read More

Tm Bioscience develops upper respiratory viral panel

Read More

GTC Biotherapeutics and LEO Pharma enter agreement for ATryn

Read More

Positive outcome for BEMA-fentanyl in comparative pharmacokinetics study

Read More

Alnylam seeks clearance for phase I study of ALN-RSV01 for RSV

Read More

Antiviral FluCide-I begins preclinical studies

Read More

DOR BioPharma to acquire Gastrotech Pharma

Read More

NF-676: novel and potent use-dependent blocker of RyR1

Read More

SL-650155 reveals effects of serotonin in models of amnesia

Read More

ACTOplus met available in U.S. for type 2 diabetes

Read More

Novel agents for the treatment of neurological disorders disclosed in recent patents

Read More

Recent patents report compounds with potential use in the treatment of respiratory disorders

Read More

New treatments for cancer covered in recent patents

Read More

In vitro effects of anti-TNF-alpha agents on apoptosis and cytotoxicity

Read More

AT-001 reported effective in the treatment of rheumatoid arthritis

Read More

AmPrbetaCD: a novel anthrax lethal toxin inhibitor

Read More

Update on the therapeutic benefits of quetiapine in psychological disorders

Read More

Acadia presents a new potent, orally available, isoform-selective RARbeta2 agonist

Read More

Phase I data on tgAAC94 in inflammatory arthritis

Read More

Clinical evidence confirms transdermal selegiline is safe in patients with major depression

Read More